Annals of hepatology
Alpha-1 antitrypsin Pi*MZ variant increases the risk of liver disease progression in MASLD and MASH.
Bradley Jermy, Jack Brownrigg, Pavel Strnad, Rohit Loomba
Published: 202510.1016/j.aohep.2025.102143
Abstract
INTRODUCTION AND OBJECTIVES: Most investigational treatments for metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) show modest anti-fibrotic effects, likely due to a multifact…
Preview only. Read the full abstract at the source